CLINICAL INVESTIGATION RESULT VALUE
 Related DDCN/DSCN/ISN
Description Where Used Data Elements

Data Elements:
ALPHA FETOPROTEIN
ALPHA FETOPROTEIN (CEREBROSPINAL FLUID MAXIMUM AT DIAGNOSIS)
ALPHA FETOPROTEIN (SERUM MAXIMUM AT DIAGNOSIS)
BASE DEFICIT CONCENTRATION (WORST WITHIN 12 HOURS AFTER BIRTH)
BASE EXCESS CONCENTRATION
BETA HUMAN CHORIONIC GONADOTROPIN
BETA HUMAN CHORIONIC GONADOTROPIN (CEREBROSPINAL FLUID)
BETA HUMAN CHORIONIC GONADOTROPIN (MAXIMUM AT DIAGNOSIS)
BIRTH HEAD CIRCUMFERENCE IN CENTIMETRES
BIRTH LENGTH IN CENTIMETRES
BIRTH WEIGHT
BIRTH WEIGHT IN GRAMS
BLOOD GLUCOSE CONCENTRATION (ON ADMISSION TO NEONATAL CRITICAL CARE)
BLOOD GLUCOSE CONCENTRATION (ON NEONATAL CRITICAL CARE DAILY CARE DATE)
BODY MASS INDEX
BONE MARROW BLAST CELLS PERCENTAGE
BREAST CANCER INVASIVE SIZE GREATER THAN OR EQUAL TO 10mm AND LESS THAN 15mm TOTAL
BREAST CANCER INVASIVE SIZE GREATER THAN OR EQUAL TO 15mm AND LESS THAN 20mm TOTAL
BREAST CANCER INVASIVE SIZE GREATER THAN OR EQUAL TO 20mm AND LESS THAN 50mm TOTAL
BREAST CANCER INVASIVE SIZE GREATER THAN OR EQUAL TO 50mm TOTAL
BREAST CANCER INVASIVE SIZE LESS THAN 10mm TOTAL
BREAST CANCER INVASIVE SIZE NOT KNOWN TOTAL
BRESLOW THICKNESS
CD4 CELL COUNT
CELLULARITY PERCENTAGE
DIASTOLIC BLOOD PRESSURE
DIFFUSION CAPACITY TEST RESULT
DISTANCE BEYOND MUSCULARIS PROPRIA
DISTANCE FROM DENTATE LINE
DISTANCE TO CLOSEST NON PERITONEALISED CIRCUMFERENTIAL RESECTION MARGIN
DISTANCE TO MARGIN
ESTIMATED GLOMERULAR FILTRATION RATE
FORCED EXPIRATORY VOLUME IN 1 SECOND (ABSOLUTE AMOUNT)
FORCED EXPIRATORY VOLUME IN 1 SECOND (PERCENTAGE)
FRACTION OF INSPIRED OXYGEN PERCENTAGE
HEAD CIRCUMFERENCE IN CENTIMETRES
HEART RATE (ON ADMISSION TO NEONATAL CRITICAL CARE)
HUMAN CHORIONIC GONADOTROPIN
INVASIVE THICKNESS
KI-67 PERCENTAGE RESULT
LACTATE DEHYDROGENASE LEVEL (PEAK AT DIAGNOSIS)
MAXIMUM BILIRUBIN LEVEL
MEAN ARTERIAL BLOOD PRESSURE (ON ADMISSION TO NEONATAL CRITICAL CARE)
MITOTIC INDEX (SARCOMA CANCER)
MITOTIC INDEX (SKIN CANCER)
NODAL STATUS OF TUMOUR NUMBER OF LYMPH NODES SAMPLED
NODAL STATUS OF TUMOUR NUMBER OF NEGATIVE LYMPH NODES SAMPLED
NODAL STATUS OF TUMOUR NUMBER OF POSITIVE LYMPH NODES SAMPLED
NUMBER OF ABNORMAL NODAL AREAS
NUMBER OF LIVER TUMOURS
NUMBER OF NODES EXAMINED
NUMBER OF NODES EXAMINED (INGUINO-FEMORAL)
NUMBER OF NODES EXAMINED (LEFT-PELVIC)
NUMBER OF NODES EXAMINED (PARA-AORTIC)
NUMBER OF NODES EXAMINED (POST SENTINEL NODE COMPLETION LYMPHADENECTOMY)
NUMBER OF NODES EXAMINED (RIGHT-PELVIC)
NUMBER OF NODES EXAMINED (SENTINEL LYMPH NODES)
NUMBER OF NODES POSITIVE
NUMBER OF NODES POSITIVE (INGUINO-FEMORAL)
NUMBER OF NODES POSITIVE (LEFT NECK)
NUMBER OF NODES POSITIVE (LEFT PELVIC)
NUMBER OF NODES POSITIVE (PARA-AORTIC)
NUMBER OF NODES POSITIVE (POST SENTINEL NODE COMPLETION LYMPHADENECTOMY)
NUMBER OF NODES POSITIVE (RIGHT NECK)
NUMBER OF NODES POSITIVE (RIGHT PELVIC)
NUMBER OF NODES POSITIVE (SENTINEL LYMPH NODES)
NUMBER OF RECTAL WASHOUTS
OMENTAL DEPOSIT SIZE
OXYGEN SATURATION (ON ADMISSION TO NEONATAL CRITICAL CARE)
PARTIAL PRESSURE CARBON DIOXIDE
PERSON HEIGHT IN CENTIMETRES
PERSON HEIGHT IN METRES
PERSON HEIGHT IN METRES (START OF SYSTEMIC ANTI-CANCER THERAPY DRUG REGIMEN)
PERSON LENGTH IN CENTIMETRES
PERSON WEIGHT
PERSON WEIGHT (START OF SYSTEMIC ANTI-CANCER THERAPY DRUG CYCLE)
PERSON WEIGHT (START OF SYSTEMIC ANTI-CANCER THERAPY DRUG REGIMEN)
PERSON WEIGHT IN GRAMS
PH LEVEL
PROSTATE SPECIFIC ANTIGEN (AT DIAGNOSIS)
RESPIRATORY RATE (ON ADMISSION TO NEONATAL CRITICAL CARE)
SYSTOLIC BLOOD PRESSURE
TEMPERATURE (ON ADMISSION TO NEONATAL CRITICAL CARE)
TUMOUR HEIGHT ABOVE ANAL VERGE
TUMOUR NECROSIS PERCENTAGE
TURP TUMOUR PERCENTAGE
UMBILICAL CORD BLOOD BASE EXCESS CONCENTRATION (ARTERIAL)
UMBILICAL CORD BLOOD BASE EXCESS CONCENTRATION (VENOUS)
UMBILICAL CORD BLOOD LACTATE LEVEL
UMBILICAL CORD BLOOD PARTIAL PRESSURE CARBON DIOXIDE (ARTERIAL)
UMBILICAL CORD BLOOD PARTIAL PRESSURE CARBON DIOXIDE (VENOUS)
UMBILICAL CORD BLOOD PH LEVEL (ARTERIAL)
UMBILICAL CORD BLOOD PH LEVEL (VENOUS)
UNINVOLVED CERVICAL STROMA THICKNESS
VIRAL LOAD COUNT
WHITE BLOOD CELL COUNT
WHITE BLOOD CELL COUNT (HIGHEST PRETREATMENT)